Open AccessPigment epithelium‐derived factor: a key mediator in bone homeostasis and potential for bone regenerative therapy
Author(s) -
BaxterHolland Mia,
Dass Crispin R.
Publication year - 2018
Publication title -
journal of pharmacy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.745
H-Index - 118
eISSN - 2042-7158
pISSN - 0022-3573
DOI - 10.1111/jphp.12942
Subject(s) - mediator , homeostasis , bone formation , key (lock) , medicine , microbiology and biotechnology , chemistry , biology , ecology
Abstract Objectives Pigment epithelium‐derived factor ( PEDF ), a multifunctional endogenous glycoprotein, has a very wide range of biological actions, notably in bone homeostasis. The question has been raised regarding the place of PEDF in the treatment of bone disorders and osteosarcoma, and its potential for tumour growth suppression. Methods The PubMed database was used to compile this review. Key findings Pigment epithelium‐derived factor's actions in osteoid tissues include promoting mesenchymal stem cell commitment to osteoblasts, increasing matrix mineralisation, and promoting osteoblast proliferation. It shows potential to improve therapeutic outcomes in treatment of multiple cancer types and regrowth of bone after trauma or resection in animal studies. PEDF may possibly have a reduced adverse effect profile compared with current osteo‐regenerative treatments; however, there is currently very limited evidence regarding the safety or efficacy in human models. Summary Pigment epithelium‐derived factor is very active within the body, particularly in osseous tissue, and its physiological actions give it potential for treatment of both bone disorders and multiple tumour types. Further research is needed to ascertain the adverse effects and safety profile of PEDF as a therapeutic agent.